Nicole Lamanna, MD
Medical Oncology · New York, NYNPI 1164493102
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $91,095 of the $106,272 with a category attached, or 85.7%. 21 manufacturers reported payments, led by AstraZeneca at 26.0% of the total. Reporting peaked in 2019 at $30,908 and has fallen 56.4% since, to $13,475 in 2025.
Across 125 payments — averaging $850.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$28K
- AbbVie$16K
- Beigene USA, Inc.$12K
- Janssen Global Services, LLC$11K
- Beone Medicines USA, Inc.$10K
- Bristol Myers Squibb$7K
- plus $22K from 15 others
Across 368 payments — averaging $22,430 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beigene, Ltd.$3M
- AbbVie$2.5M
- Eli Lilly$1.6M
- Beigene USA, Inc.$255K
- Beigene AUS Pty Ltd$223K
- Beone Medicines Ltd.$190K
- plus $511K from 11 others
What the payments were for
- Consulting fees$91,09586%
- Speaking & faculty fees$9,4419%
- Travel & lodging$2,0272%
- Food & beverage$3,7103%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 21 | $27,640 |
| AbbVie | 32 | $16,043 |
| Beigene USA, Inc. | 15 | $12,357 |
| Janssen Global Services, LLC | 7 | $11,470 |
| Beone Medicines USA, Inc. | 11 | $9,543 |
| Bristol Myers Squibb | 4 | $6,768 |
| Genentech, Inc. | 3 | $4,740 |
| Octapharma USA, Inc. | 4 | $3,780 |
| Lilly USA, LLC | 1 | $3,600 |
| Genmab U.S., Inc. | 3 | $3,377 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $2,949 |
| Adaptive Biotechnologies Corporation | 2 | $1,520 |
| Eli Lilly | 1 | $1,438 |
| F. Hoffmann-la Roche AG | 2 | $555 |
| Secura Bio, Inc. | 1 | $168 |
| Novartis | 8 | $152 |
| Seagen Inc. | 1 | $79 |
| Syndax Pharmaceuticals, Inc. | 1 | $35 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Morphosys, US Inc. | 1 | $17 |
| Incyte Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$106,272 in reported general payments places this provider in the 85th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammakedImmune Globul G/Gly/Iga Avg 46 | 26 | $76,465 |
| EliquisApixaban | 13 | $7,600 |
| ValacyclovirValacyclovir Hcl | 72 | $3,796 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 19 | $190 |
| Fluticasone Propionate | 13 | $165 |
| Allopurinol | 12 | $116 |
| Doxycycline Hyclate | 17 | $104 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $76 |
| Dutasteride | 12 | $41 |
| Sodium Chloride0.9 % Sodium Chloride | 13 | $23 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in New York
- Craig ThompsonNew York$4.8M
- Andrew SeidmanNew York$1.3M
- Joshua RichterNew York$971K
- Edward GelmannNew York$944K
- Ghassan Abou-AlfaNew York$825K
- Miguel PeralesNew York$769K
- Komal JhaveriNew York$642K
- Joshua BrodyNew York$492K
- Aiwu HeNew York$445K
- Raajit RampalNew York$418K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.